Breast Cancer

, Volume 17, Issue 3, pp 205–211

Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer

  • Gumersindo Pérez Manga
  • Parham Khosravi Shahi
  • Miguel Méndez Ureña
  • Rosa Quiben Pereira
  • María Isabel Palomero Plaza
  • Yann Izarzugaza Peron
  • Ricardo González Del Val
  • Joaquín Belón Carrión
  • Esperanza Pérez Cañón
  • Pilar García Alfonso
Original Article

Abstract

Background

Pathologic complete response (pCR) after preoperative systemic chemotherapy (PSCh) is associated with better outcome in locally advanced breast cancer (LABC).

Patients and methods

PSCh included: doxorubicin (A) 50 mg/m2 i.v. on day 1; docetaxel (T) 30 mg/m2 i.v. on days 1, 8 and 15; and capecitabine (X) 1,500 mg/m2/day p.o. on days 1–14, in a 4-week course repeated for up to four cycles (ATX), followed by surgery. The primary end point of this study was to evaluate the pCR rate. Secondary endpoints included clinical response rate, disease-free survival (DFS), overall survival (OS), and the toxicity profile.

Results

A total of 60 patients were included in the analysis. Median age was 49 years, and 63.3% of patients were hormone receptor positive. The median number of cycles of PSCh was four (95% CI: 3–4). Five patients (8.3%) achieved pCR in both breast and nodes, and 16.7% reached pCR only in nodes. The clinical response rate was 77% (27% complete response), but only 18% of the patients underwent conservative surgery. With a median follow-up of 20 months, 3-year DFS and OS were 76 and 90%, respectively. Grade III/IV toxicity included neutropenia (74%), febrile neutropenia (9%), mucositis (12%), and diarrhea (12%).

Conclusions

ATX every 28 days for four cycles is associated with a modest activity (low pCR rate) in the neoadjuvant setting of LABC.

Keywords

Preoperative chemotherapy Capecitabine Taxanes Anthracyclines 

References

  1. 1.
    Fisher B, Brown A, Mamounas EP, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B18. J Clin Oncol. 1997;15:2483–93.PubMedGoogle Scholar
  2. 2.
    Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–44.CrossRefPubMedGoogle Scholar
  5. 5.
    Smoot RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, et al. A single-center experience with inflammatory breast cancer, 1985–2003. Arch Surg. 2006;141:567–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Han S, Kim SB, Kang SS, Noh WC, Paik NS, Chang ES, et al. A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. Breast Cancer Res Treat. 2006;98:57–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Quiben R, Palomero MI, Cassinello J, Pérez-Manga G. Doxorubicin combined with weekly docetaxel in locally advanced or inflammatory breast cancer (BC). Goti Study Group Proc Am Soc Clin Oncol. 2001;37:1901. (abstr 1901).Google Scholar
  8. 8.
    Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, et al. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res. 2007;13:4092–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Tagaya N, Nakagawa A, Mori S, Hamada K, Suzuki N, Kubota K. Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer. Gan To Kagaku Ryoho. 2006;33:39–42.PubMedGoogle Scholar
  10. 10.
    Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, et al. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol. 2002;13:546–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11:574–89.CrossRefPubMedGoogle Scholar
  12. 12.
    Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Gianni L, Baselga L, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11:8715–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol. 2006;24:2019–27.CrossRefPubMedGoogle Scholar
  16. 16.
    Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10:6622–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91:2012–7.CrossRefPubMedGoogle Scholar
  18. 18.
    von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85.CrossRefGoogle Scholar
  19. 19.
    Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23:5983–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Heys SD, Hutcheon AW, Sarkar TK. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3:S69–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Khosravi P, Pérez-Manga G. La relevancia clínica de la sobreexpresión de HER-2 en el cáncer de mama. An Med Int. 2006;23:103–4.Google Scholar
  22. 22.
    Wenzel C, Hussian D, Bartsch R, Pluschnig U, Locker GJ, Rudas M, et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol. 2004;30:400–4.Google Scholar
  23. 23.
    Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.CrossRefPubMedGoogle Scholar
  24. 24.
    Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008;112:1455–61.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Gumersindo Pérez Manga
    • 1
  • Parham Khosravi Shahi
    • 1
  • Miguel Méndez Ureña
    • 2
  • Rosa Quiben Pereira
    • 2
  • María Isabel Palomero Plaza
    • 1
  • Yann Izarzugaza Peron
    • 1
  • Ricardo González Del Val
    • 1
  • Joaquín Belón Carrión
    • 3
  • Esperanza Pérez Cañón
    • 1
  • Pilar García Alfonso
    • 1
  1. 1.Servicio de Oncología MédicaHospital General Universitario “Gregorio Marañón”MadridSpain
  2. 2.Servicio de Oncología MédicaHospital de MostolesMadridSpain
  3. 3.Servicio de Oncología MédicaHospital Virgen de las NievesGranadaSpain

Personalised recommendations